Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact
California-based biopharma company Alumis has debuted data from a trio of Phase III studies that the company says highlights the …
Post
-
-
EU clinical trial advice pilot becomes permanent
The European Medicines Agency (EMA) is permanently putting its Accelerating Clinical Trials in the EU (ACT EU) pilot into practice. The …
-
Endeavor’s Phase IIb IPF study of taladegib meets endpoints
Endeavor BioMedicines has reported that its Phase IIb WHISTLE-PF clinical trial assessing taladegib (ENV-101) achieved its primary and several key …
-
Schizophrenia research grapples with trial design hurdles in hunt for new treatments
Placebo response in acute schizophrenia trials has been rising for decades. At the same time, the observed treatment benefit is …
-
Alpheus begins multi-centre study for butterfly GBM
Alpheus Medical has begun the multi-centre Butterfly study to assess its investigational Porphyrin Metabolite Activation (PoMA) therapy in patients with …
-
Alzheimer’s disease market expected to reach $14.7bn across the 8MM by 2033
The Alzheimer’s disease market is expected to grow at a high compound annual growth rate (CAGR) of 20.0% from $2.4 …
-
BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trial
Bristol Myers Squibb’s (BMS’s) Phase III trial of Zenbexus (iberdomide) has more than doubled progression-free survival (PFS) in patients with …
-
MimiVax announces disappointing pivotal Phase IIb trial data for cancer vaccine
The pivotal SURVIVE Phase IIb trial for SurVaxM, a glioblastoma (GBM) peptide-mimic immunotherapeutic cancer vaccine developed by MimiVax, announced interesting …
-
Argenx cans Phase III Vyvgart Sjögren’s study on predicted efficacy fail
Argenx has terminated a late-stage trial evaluating its marketed therapy, Vyvgart Hytrulo (efgartigimod alfa, hyaluronidase-qvfc) in Sjögren's syndrome – dashing …
-
Lantern Pharma secures Taiwan clearances for Phase II NSCLC study
Lantern Pharma has secured regulatory and Institutional Review Board (IRB) clearances in Taiwan to initiate Part 2 of its Phase …
-
Podcast: Customising clinical trials without increasing patient burden
As highly specialised advances in clinical research have grown, so has the burden on clinicians, caregivers, and trial participants to …
-
Dignify Therapeutics secures FDA clearance for Phase I DTI-117 trial
Dignify Therapeutics has secured investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to advance DTI-117 …
-
ArriVent’s stock plummets on Phase III NSCLC trial failure
ArriVent BioPharma’s stock has dropped 46% after a Phase III trial of its non-small cell lung cancer (NSCLC) candidate failed …
-
Cerevance’s novel Parkinson’s drug nets a Phase III win
Boston-based biotech Cerevance’s first-in-class Parkinson’s therapy, solengepras, has demonstrated its potential to improve both motor and non-motor symptoms in a …
-
Taiho’s CMO Dr Keer on positive REZILIENT3 data for zipalertinib combo
Taiho Oncology chief medical officer (CMO) Dr Harold Keer recently discussed with Srivani Venna the outcomes from the Phase III REZILIENT3 …
